2026-06-30 13:00
Biovica, specializing in blood-based cancer monitoring, today announces that it has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, Inc., announced in May 2025. Under the agreement, Tempus was intended to offer DiviTum®...
2026-06-30 12:40
Biovica, specializing in blood-based cancer monitoring, today announces that it has, by mutual agreement, ended the reference laboratory agreement with Tempus AI, Inc., announced in May 2025. Under the agreement, Tempus was intended to offer DiviTum®...
2026-06-30 08:00
Annual Report for the financial year 2025/2026 for Biovica international AB is published today on our website.
2026-06-17 08:00
Strong growth provides the platform for the next commercial phase
2026-05-28 08:30
Biovica, specializing in blood-based cancer monitoring, today announced new data published in the European Journal of Cancer showing that DiviTumTKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2−...
2026-05-26 08:45
Biovica, active in blood-based cancer monitoring, today announced an expansion of an existing Pharma Services work order from a clinical-stage biopharmaceutical company developing a next-generation CDK inhibitor for solid tumors. The expanded work order...
2026-05-05 21:30
Biovica International AB (“Biovica”) today announces that the company’s Chief Financial Officer, Anders Morén, has resigned on his own initiative to pursue independent business activities.
2026-04-30 10:00
Biovica today announces that three posters including TKa measurements will be presented at ESMO Breast in Berlin on 6–8 May 2026. The presentations highlight how TKa can be used to monitor treatment response, disease progression and biological treatment...
2026-04-16 08:00
Biovica today announces that Theis Kipling will assume the role as Chief Executive Officer on May 1, 2026, earlier than previously communicated. In connection with this transition, Anders Rylander will step down as CEO and remain a member of the Board...
2026-04-07 08:30
The Biovica board has appointed Theis Kipling as the new Chief Executive Officer. He will assume the position no later than September 2026.
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects